Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Affinia Therapeutics Closes $110 Million Series B Financing
Affinia TherapeuticsMay 3, 2021 GMT Financing co-led by EcoR1 Capital and Farallon Capital Management
Proceeds to support continued development of proprietary platform for rationally designed adeno-associated virus vectors (AAV) and advance programs into the clinic
WALTHAM, Mass., May 03, 2021 (GLOBE NEWSWIRE) Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and non-rare diseases, today announced it has closed an oversubscribed $110 million Series B financing with a premier syndicate of life science investors, co-led by EcoR1 Capital and Farallon Capital Management. Additional new investors participating in the round include Avidity Partners, Casdin Capital, GV (formerly Google Ventures), Octagon Cap
Samir Mody as chief commercial officer, while
Friedrich Asmus signs on as SVP, clinical development and medical affairs. Meanwhile, the company has also tapped
Joel Centeno as SVP, manufacturing, quality and supply chain. Mody comes over from Medtronic, where he was vice president, CRHF strategy, health economics and reimbursement. Asmus previously served as VP of clinical development at ophthalmology biotech ProQR Therapeutics, while Centeno comes over after stints at Boston Scientific, Hologic and AltheaDx.
> Antios Therapeutics has tapped
Tamra Adams as chief financial officer, a newly created executive position at the company. Before joining Antios, Adams founded Accounting Concepts, which provided CFO, accounting, and financial services to emerging growth companies in the biopharmaceutical and information technology industries, including Engage Therapeutics.
Home / Top News / Affinia Therapeutics Announces Addition of Gene Therapy Scientific and Medical Experts to Leadership Team to Advance Novel Gene Therapy Platform and Programs to the Clinic
Affinia Therapeutics Announces Addition of Gene Therapy Scientific and Medical Experts to Leadership Team to Advance Novel Gene Therapy Platform and Programs to the Clinic Gene editing expert Charles Albright, Ph.D., joins as chief scientific officer Gene therapy development expert Petra Kaufmann, M.D.,
joins as chief medical officer –
WALTHAM, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and non-rare diseases, today announced the completion of its leadership team. Collectively, the executives represent a diverse team of proven leaders in gene therapy who have successfully developed novel platforms and translated the